{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:44:08Z","timestamp":1788983048055,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T00:00:00Z","timestamp":1338940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s12032-012-0262-4","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T18:18:42Z","timestamp":1338920322000},"page":"3561-3569","source":"Crossref","is-referenced-by-count":50,"title":["Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"29","author":[{"given":"Farhad","family":"Jadidi-Niaragh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Jeddi-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Ansaripour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohsen","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan Ali","family":"Sharifian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazel","family":"Shokri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,6]]},"reference":[{"issue":"8","key":"262_CR1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"262_CR2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00262-005-0675-4","volume":"55","author":"H Mellstedt","year":"2006","unstructured":"Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother. 2006;55(2):210\u201320.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"262_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0268-960X(90)90044-S","volume":"4","author":"S Zaknoen","year":"1990","unstructured":"Zaknoen S, Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev. 1990;4(3):165\u201374.","journal-title":"Blood Rev"},{"issue":"2","key":"262_CR4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1983.tb02096.x","volume":"54","author":"F Lauria","year":"1983","unstructured":"Lauria F, Foa R, Mantovani V, Fierro M, Catovsky D, Tura S. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol. 1983;54(2):277\u201383.","journal-title":"Br J Haematol"},{"issue":"6","key":"262_CR5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018.","journal-title":"Blood"},{"issue":"3","key":"262_CR6","first-page":"677","volume":"20","author":"K Giannopoulos","year":"2008","unstructured":"Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20(3):677.","journal-title":"Oncol Rep"},{"issue":"3","key":"262_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what\u2019s in a name? Nat Rev Immunol. 2004;4(3):231\u20137.","journal-title":"Nat Rev Immunol"},{"key":"262_CR8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","volume":"26","author":"M Kronenberg","year":"2005","unstructured":"Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;26:877\u2013900.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"262_CR9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0167-5699(00)01735-7","volume":"21","author":"DI Godfrey","year":"2000","unstructured":"Godfrey DI, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21(11):573\u201383.","journal-title":"Immunol Today"},{"issue":"1","key":"262_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5603\/FHC.2011.0025","volume":"49","author":"I Hus","year":"2011","unstructured":"Hus I, Staroslawska E, Bojarska-Junak A, Dobrzynska-Rutkowska A, Surdacka A, Wdowiak P, et al. CD3(+)\/CD16(+)CD56(+) cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma. Folia Histochem Cytobiol. 2011;49(1):183\u20137.","journal-title":"Folia Histochem Cytobiol"},{"issue":"1","key":"262_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2001-12-0196","volume":"100","author":"CH Kim","year":"2002","unstructured":"Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood. 2002;100(1):11\u20136.","journal-title":"Blood"},{"key":"262_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-230X(08)00408-9","volume":"101","author":"M Terabe","year":"2008","unstructured":"Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277\u2013348.","journal-title":"Adv Cancer Res"},{"issue":"6","key":"262_CR13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/156652409788970706","volume":"9","author":"JA Berzofsky","year":"2009","unstructured":"Berzofsky JA, Terabe M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med. 2009;9(6):667\u201372.","journal-title":"Curr Mol Med"},{"issue":"12","key":"262_CR14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","volume":"197","author":"MV Dhodapkar","year":"2003","unstructured":"Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii SI, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003;197(12):1667.","journal-title":"J Exp Med"},{"issue":"20","key":"262_CR15","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","volume":"11","author":"T Tachibana","year":"2005","unstructured":"Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, et al. Increased intratumor V alpha 24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005;11(20):7322\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"262_CR16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3892\/or_00000924","volume":"24","author":"A Bojarska-Junak","year":"2010","unstructured":"Bojarska-Junak A, Hus I, Sieklucka M, Wasik-Szczepanek E, Mazurkiewicz T, Polak P, et al. Natural killer-like T CD3+\/CD16+ CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol Rep. 2010;24(3):803\u201310.","journal-title":"Oncol Rep"},{"issue":"10","key":"262_CR17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.leu.2403083","volume":"17","author":"H Guven","year":"2003","unstructured":"Guven H, Gilljam M, Chambers B, Ljunggren H, Christensson B, Kimby E, et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003;17(10):1973\u201380.","journal-title":"Leukemia"},{"issue":"15","key":"262_CR18","first-page":"4516","volume":"63","author":"T Azuma","year":"2003","unstructured":"Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 2003;63(15):4516.","journal-title":"Cancer Res"},{"key":"262_CR19","doi-asserted-by":"crossref","unstructured":"Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang C-R, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One. 2011;6(6):e20702.","DOI":"10.1371\/journal.pone.0020702"},{"issue":"3","key":"262_CR20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ijc.11723","volume":"109","author":"F Fais","year":"2004","unstructured":"Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates \u03b1-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer. 2004;109(3):402\u201311.","journal-title":"Int J Cancer"},{"issue":"12","key":"262_CR21","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2014working group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood"},{"issue":"12","key":"262_CR22","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2019Brien S, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990\u20137.","journal-title":"Blood"},{"issue":"2","key":"262_CR23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack B. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219\u201334.","journal-title":"Blood"},{"issue":"6","key":"262_CR24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1160\/TH05-06-0445","volume":"94","author":"S Gharagozlou","year":"2005","unstructured":"Gharagozlou S, Kardar GA, Rabbani H, Shokri F. Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII. THROMB HAEMOSTASIS-STUTTGART. 2005;94(6):1131.","journal-title":"THROMB HAEMOSTASIS-STUTTGART"},{"issue":"2","key":"262_CR25","first-page":"525","volume":"54","author":"A Dickinson","year":"1983","unstructured":"Dickinson A, George S, Proctor S. T cell subpopulations in CLL: methods of T cell enrichment artificially alter proportions of OKT4 and OKT8 positive cells. Clin Exp Immunol. 1983;54(2):525.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"262_CR26","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/j.1349-7006.2009.01341.x","volume":"100","author":"M Hojjat-Farsangi","year":"2009","unstructured":"Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Mellstedt H, Shokri F, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci. 2009;100(12):2346\u201353.","journal-title":"Cancer Sci"},{"issue":"1","key":"262_CR27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","volume":"87","author":"A Hamblin","year":"2008","unstructured":"Hamblin A, Hamblin T. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87(1):49.","journal-title":"Br Med Bull"},{"issue":"9","key":"262_CR28","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.4049\/jimmunol.1100794","volume":"187","author":"O Patel","year":"2011","unstructured":"Patel O, Cameron G, Pellicci DG, Liu Z, Byun H-S, Beddoe T, et al. NKT TCR recognition of CD1d-alpha-C-galactosylceramide. J Immunol. 2011;187(9):4705\u201313.","journal-title":"J Immunol"},{"key":"262_CR29","doi-asserted-by":"crossref","unstructured":"Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 2011;117(10):2163\u20139.","DOI":"10.1002\/cncr.25752"},{"issue":"7","key":"262_CR30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.it.2006.05.003","volume":"27","author":"A La Cava","year":"2006","unstructured":"La Cava A, Van Kaer L, Fu-Dong Sh. CD4+ CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006;27(7):322\u20137.","journal-title":"Trends Immunol"},{"issue":"5","key":"262_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1745-7270.2008.00410.x","volume":"40","author":"W Li","year":"2008","unstructured":"Li W, Ji F, Zhang Y, Wang Y, Yang N, Ge H, et al. Cooperation of invariant NKT cells and CD4(+)CD25(+) T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide. Acta Biochim Biophys Sin. 2008;40(5):381\u201390.","journal-title":"Acta Biochim Biophys Sin"},{"key":"262_CR32","doi-asserted-by":"crossref","unstructured":"Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, et al. Cooperation of invariant NKT cells and CD4(+)CD25(+) T regulatory cells in the prevention of autoimmune myasthenia (vol 175, pg 7898, 2005). J Immunol. 2006;176(11):7130.","DOI":"10.4049\/jimmunol.176.11.7130-a"},{"issue":"2","key":"262_CR33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4049\/jimmunol.173.2.1043","volume":"173","author":"K Roelofs-Haarhuis","year":"2004","unstructured":"Roelofs-Haarhuis K, Wu XZ, Gleichmann E. Oral tolerance to nickel requires CD4(+) invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol. 2004;173(2):1043\u201350.","journal-title":"J Immunol"},{"issue":"4","key":"262_CR34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/eji.200425899","volume":"35","author":"SP Jiang","year":"2005","unstructured":"Jiang SP, Game DS, Davies D, Lombardi G, Lechler RI. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4(+)CD25(+) regulatory T cells? Eur J Immunol. 2005;35(4):1193\u2013200.","journal-title":"Eur J Immunol"},{"issue":"11","key":"262_CR35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1248\/bpb.18.1487","volume":"18","author":"K Motoki","year":"1995","unstructured":"Motoki K, Morita M, Kobayashi E, Uchida T, Akimoto K, Fukushima H, Koezuka Y. Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties. Biol Pharm Bull. 1995;18(11):1487\u201391.","journal-title":"Biol Pharm Bull"},{"issue":"5343","key":"262_CR36","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.278.5343.1623","volume":"278","author":"J Cui","year":"1997","unstructured":"Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for V\u03b114 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278(5343):1623.","journal-title":"Science"},{"issue":"1","key":"262_CR37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1084\/jem.20020092","volume":"196","author":"NY Crowe","year":"2002","unstructured":"Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med. 2002;196(1):119.","journal-title":"J Exp Med"},{"issue":"6","key":"262_CR38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/82771","volume":"1","author":"M Terabe","year":"2000","unstructured":"Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell\u2013mediated repression of tumor immunosurveillance by IL-13 and the IL-4R\u2013STAT6 pathway. Nat Immunol. 2000;1(6):515\u201320.","journal-title":"Nat Immunol"},{"issue":"6","key":"262_CR39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/82782","volume":"1","author":"AM Moodycliffe","year":"2000","unstructured":"Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol. 2000;1(6):521\u20135.","journal-title":"Nat Immunol"},{"issue":"11","key":"262_CR40","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20022227","volume":"198","author":"M Terabe","year":"2003","unstructured":"Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, et al. Transforming growth factor-\u03b2 production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte\u2013mediated tumor immunosurveillance. J Exp Med. 2003;198(11):1741.","journal-title":"J Exp Med"},{"issue":"12","key":"262_CR41","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1002\/ijc.21764","volume":"118","author":"GJ Renukaradhya","year":"2006","unstructured":"Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, Brutkiewicz RR. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer. 2006;118(12):3045\u201353.","journal-title":"Int J Cancer"},{"issue":"12","key":"262_CR42","first-page":"3702","volume":"8","author":"G Giaccone","year":"2002","unstructured":"Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand \u03b1-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8(12):3702\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"262_CR43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.leukres.2004.06.005","volume":"29","author":"K Yoneda","year":"2005","unstructured":"Yoneda K, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, et al. The peripheral blood V [alpha] 24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res. 2005;29(2):147\u201352.","journal-title":"Leuk Res"},{"issue":"5","key":"262_CR44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.humpath.2010.07.023","volume":"42","author":"SE Gibson","year":"2011","unstructured":"Gibson SE, Swerdlow SH, Felgar RE. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum Pathol. 2011;42(5):679\u201387.","journal-title":"Hum Pathol"},{"issue":"11","key":"262_CR45","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.4049\/jimmunol.180.11.7287","volume":"180","author":"HJJ Vliet van der","year":"2008","unstructured":"van der Vliet HJJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol. 2008;180(11):7287.","journal-title":"J Immunol"},{"issue":"4","key":"262_CR46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.leu.2403671","volume":"19","author":"F Fais","year":"2005","unstructured":"Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D, et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 2005;19(4):551\u20136.","journal-title":"Leukemia"},{"issue":"7","key":"262_CR47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ajh.21743","volume":"85","author":"C Xu","year":"2010","unstructured":"Xu C, de Vries R, Visser L, Diepstra A, Gadola SD, Poppema S, et al. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol. 2010;85(7):539.","journal-title":"Am J Hematol"},{"issue":"4","key":"262_CR48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.2003.04465.x","volume":"122","author":"S Fujii","year":"2003","unstructured":"Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-\u03b3-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol. 2003;122(4):617\u201322.","journal-title":"Br J Haematol"},{"issue":"10","key":"262_CR49","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1080\/10428190600682688","volume":"47","author":"K Haraguchi","year":"2006","unstructured":"Haraguchi K, Takahashi T, Nakahara F, Matsumoto A, Kurokawa M, Ogawa S, et al. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma. 2006;47(10):2218\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"262_CR50","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","volume":"17","author":"LS Metelitsa","year":"2003","unstructured":"Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17(6):1068\u201377.","journal-title":"Leukemia"},{"issue":"10","key":"262_CR51","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1073\/pnas.95.10.5690","volume":"95","author":"T Kawano","year":"1998","unstructured":"Kawano T, Cui JQ, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V alpha 14 NKT cells. Proc Nat Acad Sci USA. 1998;95(10):5690\u20133.","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3","key":"262_CR52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.179.3.999","volume":"179","author":"M Lotz","year":"1994","unstructured":"Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994;179(3):999\u20131004.","journal-title":"J Exp Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0262-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-012-0262-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0262-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:16:34Z","timestamp":1594206994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-012-0262-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,6]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s12032-012-0262-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,6]]}}}